Q32 Bio (QTTB)

• Market cap: $34.3M
• 1 day: 1.81%
• 5 days: -5.07%
• 1 month: 41.92%
• 3 months: 26.58%
• 6 months: 75.63%
• Year to date: -18.55%
• 1 year: -94.05%
• 5 years: -98.49%
• 10 years: -99.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Employees: 27